Steward Partners Investment Advisory’s Tarsus Pharmaceuticals TARS Stock Holding History

Steward Partners Investment Advisory’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.34K	Hold	69	–	–	﹤0.01%	4021
2026 Q1	$4.84K	Hold	69	–	–	﹤0.01%	3809
2025 Q4	$5.65K	Sell	69 -3	-4%	-$224	﹤0.01%	3658
2025 Q3	$4.28K	Buy	+72	New	+$3.54K	﹤0.01%	3703
2024 Q2	–	Sell	-59	Closed	-$2.15K	–	3713
2024 Q1	$2.15K	Hold	59	–	–	﹤0.01%	3278
2023 Q4	$1.2K	Hold	59	–	–	﹤0.01%	3287
2023 Q3	$1.05K	Hold	59	–	–	﹤0.01%	3181
2023 Q2	$1.07K	Buy	+59	New	+$938	﹤0.01%	3126

Other funds holding TARS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Steward Partners Investment Advisory's TARS Position: Q2 2026 in Review

Steward Partners Investment Advisory held its Tarsus Pharmaceuticals (TARS) position steady in Q2 2026 at 69 shares worth $4.34K. The position accounts for ﹤0.01% of the portfolio, ranked #4021.

Steward Partners Investment Advisory first reported a position in TARS in Q2 2023 and has held it in 8 quarters since. The position peaked at $5.65K in Q4 2025. 234 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

Steward Partners Investment Advisory held 69 shares of Tarsus Pharmaceuticals worth $4.34K as of Q2 2026.
Steward Partners Investment Advisory left its Tarsus Pharmaceuticals share count unchanged in Q2 2026.
Tarsus Pharmaceuticals made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q2 2026, its #4021 holding.
Steward Partners Investment Advisory first reported a position in Tarsus Pharmaceuticals in Q2 2023 and has held it in 8 quarters since.
Steward Partners Investment Advisory's Tarsus Pharmaceuticals position peaked at $5.65K in Q4 2025.
234 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q2 2026, filed 13 Aug 2026.